FDA Releases Guidance on Investigational New Drug Applications for Unrelated Allogeneic Placental/Umbilical Cord Blood

Summary

The Food and Drug Administration (FDA) has made available a guidance document to help industry staff and sponsors prepare investigational new drug applications for hematopoietic progenitor cells from placental/umbilical cord blood, which can be used to treat patients with hematopoietic disorders